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Abstract
The combination of surgical procedure (open or endoscopic techniques), rehabilitation 
and antioxidant therapy (Alpha lipoic acid, curcumin) is superior to monotherapies in 
the prognosis and recovery of patients with this pathology. The prescription of these 
medications by their mechanisms of action should be allocated prior to decompression 
surgery and should continue receiving medication during the rehabilitation time. Clinical 
and electrophysiological follow-ups are required to verify the improvement.
Keywords: carpal tunnel syndrome, median nerve entrapment,  
compression neuropathy
1. Definition
The American Academy of Orthopedic Surgeons (AAOS) defines the carpal tunnel syndrome 
(CTS) as the most common form of entrapment neuropathy of the median nerve, and the syn-
drome affects 3.8% of the general population [1], with an incidence in both genders of 376 per 
100,000 US habitants [2] combined and with a prevalence that usually varies in relation to the 
risk factors of a specific population; a study among poultry processing employees reported an 
estimated prevalence of 42%. CTS is one of the most common clinical problems encountered 
by hand surgeons. Although this syndrome is widely recognized, its etiology remains largely 
unclear [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Anatomy
The median nerve (MN) derives from the brachial plexus as a terminal branch of the medial 
and lateral cord. The fibers from the lateral cord (C6–7) provide sensitivity to the thumb, the 
index and the middle finger, as well as the motor fibers of the proximal muscles innervated 
by the median nerve (palmar muscles, pronator teres muscle). The medial cord (C8-T1) sup-
plies most of the motor fibers to the distal muscles of the forearm and the hand, as well as the 
sensitivity to the external part of the ring finger. The MN descends through the arm without 
creating any branches until it reaches the forearm, just beneath the head of the pronator teres 
muscle, where its most important branch originates, the anterior interosseous nerve of the 
forearm. This nerve supplies the flexor pollicis longus, flexor digitorum profundus and pro-
nator quadratus. Multiple muscular branches arise from the MN during its path, which sup-
ply the pronator teres, flexor carpi radialis, palmaris longus and flexor digitorum superficialis 
muscles. Proximal to the wrist and the carpal tunnel (CT), the palmar branch of the median 
nerve emerges and innervates the skin of the thenar eminence [4] (Figure 1).
In the palm of the hand, the MN sends a motor branch to the lumbricals of the index and the 
middle finger as well as a recurrent branch to innervate the muscles of the thenar eminence 
(abductor pollicis brevis, flexor pollicis brevis and opponens pollicis). The proper palmar 
Figure 1. Median nerve pathway.
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digital nerves are sensory fibers that supply the skin of the index and the middle fingers as 
well as the medial part of the ring finger and medial surface of the thumb [4] (Figure 1). There 
are multiple anatomical variants in the path and distribution of the MN, which could be pres-
ent in up to 11% of the population. The most common variants are the presence of a medial 
residual artery, which is an embryological remnant that usually suffers a regression in the sec-
ond trimester but could persist in 5% of the population, and it is also related to the presence 
of the CTS, and the anastomosis of Martin Gruber, which is a motor communication between 
the median and ulnar nerve at the forearm, which could have its origin from the union of the 
principal fibers of these nerves or in the anastomosis of the anterior interosseous nerve with 
the ulnar nerve and it is present in 5–10% of the population [5].
The carpal tunnel connects the anterior compartment of the forearm to the palm of the hand. 
It is delimited medially by the pisiform bone, laterally by the hamulus of the unciform bone, 
posteriorly by the scaphoid bone and the trapezoid bone and its roof by the transverse carpal 
ligament. It can be divided into three portions:
1. Proximal: it includes the volar carpal ligament, originated in the forearm.
2. Medial: the space comprehended between the pisiform bone and the unciform bone, and it 
has approximately 20 mm of width and a transversal area of 1.6 cm2.
3. Distal: it corresponds to the origin of the palmar aponeurosis.
Many structures pass through the carpal tunnel, such as eight flexor tendons of the fingers (four 
superficialis and four profundus) and the flexor pollicis longus, and usually the localization of the 
median nerve is superficial to the tendons and medial to the flexor pollicis longus [4] (Figure 2).
Figure 2. Anatomical elements involved in the procedure to open the transverse carpal ligament.
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3. Physiopathology of carpal tunnel syndrome
CTS is generally conceded as disarrangement caused by a decoupling of the size of the com-
ponents of the carpal tunnel, and the space delimited by the fibrous and osseous structures. 
This is what conditions the compression of the median nerve, altering its irrigation. The 
compression of the components within the carpal tunnel induces venous congestion and epi-
neural edema, consequently inducing fibroblast invasion in the affected tissue causing con-
striction and fibrosis of the endoneural compartment of the median nerve. The edema and the 
epineural and endoneural compression interrupt the axoplasmic flow of nutrients and ions 
and cause the median nerve to become enlarged [6].
Furthermore, the most common diagnosis is idiopathic CTS; nevertheless, recent studies that 
used magnetic resonance imaging (MRI), histological and biomechanical techniques have 
strongly suggested that abnormalities of the synovial tissue within the carpal tunnel are 
closely related to the development of idiopathic CTS, which means that subsynovial connec-
tive tissue may be predisposed to shear injury from activity done in 60° of wrist flexion [7].
4. New components to be highlighted in physiopathology of CTS
4.1. Effect of ischemia/reperfusion in the progression of the nervous injury in the 
carpal tunnel syndrome
The symptoms of CTS are caused by increased pressure within the carpal tunnel, and 
therefore, a decreased function of the median nerve. Nerve damage is attributed to restric-
tion of blood flow in the endoneural capillary system, leading to alterations in the blood-
nerve barrier structure and resulting in endoneural edema, venous congestion, ischemia 
and subsequent metabolic abnormalities. The ischemia-reperfusion injury of the median 
nerve results in oxidative stress and inflammation of the subsynovial connective tissue, 
and it has been proposed that this could have major contribution in the evolution of idio-
pathic CTS.
The intermittent compression of the vascular-nervous plexus due to a reduction of lumen of 
the carpal tunnel is one of the pathophysiological processes that is suspected to be the cause 
of development of CTS [1–6]. Nervous tissue has a very small capacity to tolerate ischemia 
(<20 min), which makes this tissue very vulnerable to be damaged [2–4, 6–10]; the component 
of narrowing of the carpal tunnel is intermittent, but persistent, which means that the injury 
is not presented acutely but rather progresses chronically [8–10].
The ischemia/reperfusion (I/R) phenomenon begins with an occlusion of arterial or venous 
blood flow to a tissue or an organ (ischemia); this interruption in the perfusion to the tissue 
will develop a direct injury in a limited area due to the ischemia, and this occurs in a specific 
time and depends on the affected organ (musculoskeletal, cardiac, renal, neuronal, adipose, 
tendinous, etc.). When the blood flow is restored (reperfusion), multiple local and systemic 
mechanisms will be activated in the affected area, which implies an increase of injury, known 
as I/R injury. The extension of this depend on the perfusion area of the affected vessel, the 
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time of ischemia and the repeated number of I/R events. Initially, it leads to an acute lesion 
proper of the phenomenon, then a major extension of the damage secondary to the repetition 
of I/R events, since in the CTS, it occurs in an intermittent and prolonged way [7, 10–12].
4.2. Components of the I/R injury in the carpal tunnel syndrome
There are multiple components in the I/R phenomenon [10, 12]; however, the most important 
components in the pathological development of the carpal tunnel are as follows: (1) increase 
in the cytosolic cations’ concentration (change in the permeability of the membrane), (2) mito-
chondrial lesion (alteration of the ATP production and oxidative stress), (3) oxidative stress 
(production of reactive oxygen and nitrogen species coupled by disruption of redox reaction), 
(4) immunity-mediated lesion and (5) transcriptional reprogramming [11, 12] (Figure 3).
4.3. Alteration of the cellular membrane permeability
The activation of multiple transporters in the cellular membrane during the I/R phenomenon 
will lead to major changes (related to cellular microenvironment) in the calcium (Ca2+) and 
Figure 3. I/R components in carpal tunnel syndrome and pathophysiological events in the damage of local tissues.
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sodium (Na+) concentration. The movement of these cations through the membrane will be 
accompanied by water molecules that migrate from the extracellular space into intracellu-
lar and vice versa, making changes in the cellular volume leading to cellular and interstitial 
edema [9, 13, 14]. This edema expressed exclusively by the affected tissue will impact all the 
cellular groups in the adjacency such as nervous, adipose, muscular and endothelial cells 
from the structure of the carpal tunnel, and it can be accompanied by nervous or endothelial 
injury that will manifest with changes in the volumes of water in different compartments. 
These changes will produce secondary and interstitial compartment syndrome followed by 
edema, extended ischemia and local necrosis [9, 13–15].
4.4. Mitochondrial lesion
The mitochondria participate in multiple cellular activities such as ATP production and mod-
ulation of the redox state of the cell. The ATP production over the injury process is interrupted 
by a blocked complex in the respiratory chain (complexes III and IV), depletion of meta-
bolic substrates (ADP, Pi, pyruvate, etc.) and high production of nitric oxide (NO*) [15, 16]. 
The mitochondrial injury translates as a failure to adapt to the deprivation of oxygen and 
an OS overload to the enzymatic scavenger of the mitochondria in the affected cells by I/R 
phenomenon [16, 17]. If the lesion is substantial, it will be followed by fission processes of the 
mitochondria (fragmentation), loss of function and loss of the membrane potential [16, 17].
4.5. Oxidative stress and signaling redox
The blockage of the respiratory chain in the mitochondria increases the amount of oxidative 
stress (OS), leading to a production of reactive oxygen species (ROS) such as superoxide anion 
(O
2
*) and mainly, hydrogen peroxide (H
2
O
2
). The increase in the production of NO* combined 
with the overproduction of ROS (in the phase of reperfusion) and the overload of scavenger 
systems in the mitochondria will magnify the production of reactive nitrogen species (RNS), 
primarily peroxynitrite (ONOO*) [18–20].
The cells that present mitochondrial injury coupled with loss of mitochondrial membrane 
potential, “point of safe return” (PSR), will cause opening of mitochondrial permeability tran-
sitional pores (mPTP). The opening of these pores will liberate all mitochondrial ROS and 
RNS gathered in the matrix that will subsequently interact with cellular components (mostly 
lipids, proteins, nucleic acids), corrupting the function and triggering mechanisms of cellular 
apoptosis and autophagy [19–21].
The ROS and RNS production (OS) alters the function of the cell and make changes in the 
signaling redox of the adjacent survivor cells [22, 23], as some species of free radicals have 
the capacity to travel up to 400 nm in distance (ONOO*) causing disturbance in the func-
tion and the configuration of membrane components and organelles in other healthy cells. 
By modifying redox signaling, the affected cells that survived the initial lesion can trigger a 
transcriptional reprogramming that will lead them to gene expressions of cellular injury such 
as pro-inflammatory cytokine receptors, making them susceptible to apoptosis induced by 
immunity-mediated cells [23].
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4.6. Immunity-mediated lesion
The I/R lesion will activate three types of inflammatory responses such as sterile, adaptive 
and innate [11, 24]. The three kinds of immunity are activated by the OS activity generated in 
the mitochondria of affected cells by the initial lesion and the liberation of cellular material of 
necrotic cells (DNA, RNA, lysosomes, proteases, glucosidases, ATP, ADP, etc.), and this will 
secondarily result in the activation and differentiation of inflammatory cells, producing an adap-
tive response. In the lesion by IR, the toll-like receptors (TLRs) will be expressed in the cellular 
membrane, principally TLR2 and TLR4 [25]. Sterile immunity is characterized by the recruit-
ment of neutrophils and macrophages and also by the production of pro-inflammatory and anti-
inflammatory cytokines such as IL-1β, IL-6, TNF-α and IL-10 liberated by the damaged cells. The 
expression of pro-inflammatory cytokines will induce the local activation of the immune system 
causing necrosis of the previously injured cells and increasing the extension of the lesion [26].
The activation of multiple inflammatory systems due to the I/R phenomenon will involve 
a continuous inflammation that will persist while compression exists, increasing the dam-
age; therefore, the recovery of this process will also depend on the chronicity of the injury. 
The transcriptional reprogramming of injured tissues will produce a change in some cellular 
groups, causing the expansion not only of acute but also of chronic and permanent lesion by 
the presence of fibrosis in the damaged area [27].
4.7. Transcriptional reprogramming
During the process of increased OS, disruption of signaling redox and inflammation will 
develop and result in transcriptional reprogramming, which involves a specific injured cell 
groups that will suffer a change in their structure and function, which is called epithelial mes-
enchymal transition. This produces cell mutation into pro-fibrotic phenotype cells, promoting 
permanent lesion of tissue and dysfunction of the limb [28, 29].
4.8. Clinical evaluation in CTS
In an individual with classical carpal tunnel syndrome, the most common symptom is 
pain accompanied by fingerprint weakness and numbness of the hand in the median nerve 
domain. The pain in CTS is characterized by two main pathophysiological processes: (1) acute 
ischemic pain due to compression and (2) chronic pain due to inflammation; the nervous 
tissue is the most susceptible tissue to the changes of oxygen and metabolic substrates [30]. 
The secondary lesion or death will manifest in sensation alterations and dysfunction, and the 
chronic lesion will lead to the formation of fibrosis and permanent lesion [31].
Two clinical provocation tests are useful to demonstrate severity and monitoring the pro-
gression. Phalen’s test is applied by tapping over the median nerve as it passes through the 
carpal tunnel; a positive response is defined as a sensation of tingling in the distribution of 
the median nerve in the hand. Tinel’s test is performed by hyperextending the wrist for 60 s; a 
positive response is defined as a sensation of tingling in the distribution of the median nerve 
in the hand [32].
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The Boston Carpal Tunnel Questionnaire (BCTQ) is an easy, brief, self-administered question-
naire developed by Levine et al. for the assessment of symptom severity and functional status 
of patients with CTS. A validated version of the 11-item Boston Questionnaire for CTS (score 
range 11–55) is an evaluation instrument that was recognized as reproducible, valid, with 
internal consistency and able to respond to clinical changes, accepted in many countries for 
the assessment of severity of symptoms and functional status of patients, evaluating how the 
syndrome affects daily life [33] and the follow-up of progression (Table 1).
The severity of CTS is divided into three stages are as follows:
1. The symptoms presented during the first stage are as follows: waking up with the sensa-
tion of stiffness, numbness and weakness of the hand, perceiving the hand as swollen even 
though an increase in volume is not visible, pain with variable intensity that irradiates to 
the shoulder also called brachialgia paresthetica nocturna. The pain mitigates by shaking 
or flicking the hand.
2. In the second stage, the symptoms progress to being constant all day. Repeated hand or 
wrist motion and immobility of the hand for long periods of time may exacerbate the 
symptoms. At the moment of gripping objects, patients may also feel clumsiness or 
awkwardness.
3. The third stage is characterized by hypotrophy or atrophy of the thenar eminence, with a 
variable loss in the sensibility [31].
4.9. Electrophysiology
Nerve conduction studies (NCS) have to be performed immediately before the conservative 
treatment to follow-up progression and, in case surgery is required, evaluation before surgery 
and monitoring during recovery for at least after 3 months. Electrophysiology recordings 
from the median nerve could be analyzed in the context of Dumitru’s reference values: distal 
sensory latency 3.0 ± 0.3 ms, distal sensory amplitude 15–50 μV, distal motor latency 4.2 ms 
and distal motor amplitude 13.2 ± 5 mV [34].
4.10. Treatments of CTS
Patients with mild or moderate CTS may first be offered conservative treatment. Options 
include splinting [35], corticosteroid therapy [36], physical therapy and therapeutic ultra-
sound [37, 38]. Patients with severe CTS and those whose symptoms have not improved after 
4–6 months of conservative therapy should undergo surgical decompression. Endoscopic or 
open techniques are equally effective [39]. Clinical and neurophysiological improvements can 
be observed within the first 3 months of surgery, but up to 20% of patients may experience 
persistent postoperative sensory symptoms [40, 41].
4.11. Surgical procedure
The standard technique of open carpal tunnel release has proven to be effective and safe [42, 43]. 
The classical technique consists of a 7-cm curved incision just ulnar to the thenar crease and 
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Boston Questionnaire Score
Name:
Evaluation date: ___/___/___           Surgery date: ___/___/
Hand: (___) Right (___) Left
The following questions refer to your symptoms within a typical period of 24 h during the last 2 weeks.
(1) How strong is the pain in your hand or wrist at night? 1. I feel no pain in hand or wrist at night.
2. Little pain
3. Moderate pain
4. Intense pain
5. Severe pain
(2) How many times did your hand or wrist pain wake you up in a 
typical night for the last 2 weeks?
1. Never
2. Once
3. Twice or thrice
4. Four to five times
5. More than five times
(3) Do you usually feel hand or wrist pain during the day? 1. I never feel pain during the day
2. I feel little pain during the day
3. I feel moderate pain during the day
4. I feel intense pain during the day
5. I feel severe pain during the day
(4) How often do you feel hand or wrist pain during the day? 1. Never
2. Once or twice a day
3. Three to five times a day
4. More than five times a day
5. Constant pain
(5) On average, how long do daytime pain episodes last? 1. I never feel pain during the day
2. Less than 10 min
3. From 10 to 60 min
4. More than 60 min
5. I feel constant pain during the day
(6) Do you feel your hand dormant (lost sensitiveness)? 1. No
2. I feel little dormancy
3. I feel moderate dormancy
4. I feel intense dormancy
5. I feel severe dormancy
(7) Do you feel weakness on your hand or wrist? 1. No weakness
2. Little weakness
3. Moderate weakness
4. Intense weakness
5. Severe weakness
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Boston Questionnaire Score
(8) Do you feel a tingling sensation on your hand? 1. No tingling sensation
2. Little tingling sensation
3. Moderate tingling sensation
4. Intense tingling sensation
5. Severe tingling sensation
(9) How strong is dormancy (lost sensitivity) or tingling sensation at 
night?
1. I never feel dormancy or tingling 
sensation at night
2. Little
3. Moderate
4. Intense
5. Severe
(10) How often did dormancy or tingling sensation wake you up during 
a typical night for the last 2 weeks?
1. Never
2. Once
3. Two to three times
4. Four to five times
5. More than five times
(11) How difficult do you feel in taking and using small objects such as 
keys or pens?
1. Not difficult
2. A little difficult
3. Moderately difficult
4. Very difficult
5. Severely difficult
Functional status of patients evaluates how the syndrome affects daily life
In a typical day for the last 2 weeks, have your hand or wrist symptoms brought any difficulty in performing the 
activities listed below?
Activity degree of difficulty 1. No difficulty
2. Little difficulty
3. Moderate difficulty
4. Intense difficulty
5. Cannot perform the activity at all due to 
hands and wrists symptoms
Writing 1 2 3 4 5
Buttoning clothes 1 2 3 4 5
Holding a book while reading 1 2 3 4 5
Holding the telephone hang 1 2 3 4 5
Housekeeping 1 2 3 4 5
Opening a glass vial cap 1 2 3 4 5
Carrying market bags 1 2 3 4 5
Bathing and dressing 1 2 3 4 5
Table 1. Boston questionnaire score (self-evaluation).
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 angulated over the flexion crease of the wrist in order to release the flexor retinaculum and ante-
brachial fascia under direct vision (Figure 2). Other options for an open technique consist of per-
forming a short incision of 3 cm long in the mid-palm distal to the flexion crease of the wrist to 
dissect the flexor retinaculum under a deep plane to avoid subcutaneous fat and skin, then care-
fully sectioning the transverse carpal ligament using scissors. Although open release techniques 
have proven effectiveness and safety, some studies have associated minor complications with 
open release such as scar tenderness and pillar pain in the thenar and hypothenar eminences 
[43, 44]. There is no major advantage of short incision in the palm according to various studies; the 
major advantage is the size of the scar, which is shorter when compared to the classical incision. 
The time of return to work in comparing endoscopic, short incision and a classical incision do 
not show any significant differences between these techniques according to some studies [43, 44].
Endoscopic techniques to release the carpal tunnel, either single [44] or double-portal [45], 
reduce the morbidity and have a faster recovery period. Even though it offers theoretical advan-
tages of reduced postoperative pain, quicker recovery of grip strength, fewer complications 
and faster return to everyday activities, endoscopic carpal tunnel release has not been widely 
adopted as the open techniques. It’s worth pointing out that the risk of nerve injury increases 
with these types of techniques [46]. Actually, there is no sufficient consensus to support that 
the endoscopic technique overcomes open technique regarding clinical or electrophysiologi-
cal recovery. The decision to perform endoscopic technique versus the classical or mini-open 
carpal tunnel release technique is most likely left to surgeons rather than patients, considering 
factors such as experience and resources.
4.12. From the pathophysiology to the therapeutic
The chronic lesion process will depend on the induction of I/R phenomenon on a repetitive 
pattern, in which the main pharmacological therapeutic target for regression or stopping the 
progression of the lesion would be OS modulation and inflammation.
The increase in OS production by the mitochondria in the I/R phenomenon is a key point to 
explore in the therapeutical approach to CTS, since the overproduction of ROS and RNS is 
involved in the activation of the inflammatory response and injury in the nervous cell [10, 16, 23]. 
The stimulation of the inflammation secondarily increases the production of OS; consequently, 
the therapy with antioxidants will be indicated in the acute and chronic phases of CTS.
The use of different antioxidants has been widely explored in the I/R phenomenon; however, 
there have only been made few investigations, which have had ambiguous results. From the point 
of view of evidence-based medicine, the use of antioxidants in the CTS treatment can produce a 
beneficial effect, accompanied by the decompression surgery, due to the impact in the pathophys-
iological process with the removal of the intermittent ischemic compression determined by the 
adjacent tissues in the walls and the reduction and modulation of the OS in the I/R phenomenon.
Nowadays, the most frequented phytodrugs that have shown positive results in CTS manage-
ment and are focused on OS are as follows:
1. Alpha lipoic acid
2. Curcumin
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4.12.1. Alpha lipoic acid
It is an essential substance for the function of different enzymatic components of the cells. It 
acts as a metal chelate, reducing free radicals, inflammation and modulating redox signaling. 
What stand out of this agent is the antioxidant, neuroprotective and neurotrophic properties, 
which exist in two isomeric forms such as R and S, where R plays a significant role in the pyru-
vate metabolism process and it is used in the mitochondria for the ATP generation. Its qual-
ity as metallic chelate is based on the interaction with divalent transitory metals (Mn, Cu+2, 
Pb+2 and Zn+2), and the ALA reduced form, which is dihydrolipoic acid (DHLA) (Figure 4), 
has the capacity to interact with Hg+2 and Fe+2; the inflammatory modulation is through the 
nuclear factor kappa-B (NF-kB) path, it has been reported that degradation of IkB inhibitor 
can be suppressed by multiples mechanisms, supporting the reduction in pro-inflammatory 
cytokines production. The therapeutic doses that have been used for different pathologies 
range between 100 and 1200 mg/day and at least 2 weeks of treatment are needed for positive 
results and have been safely used for up to 4 years in clinical trials [47] (Figure 4).
4.12.2. Curcumin
It is an herbal polyphenol component with potent anti-inflammatory and antioxidant prop-
erties, extracted from the Curcuma longa, which has multiple therapeutic effects in different 
pathologies (cancer, autoimmunity, inflammation, metabolism, etc.). It has great distribution 
and favorable therapeutic range; however, its absorption rate and plasma half-life are short. 
The new formulation has given this phytodrug the capacity to achieve higher plasmatic con-
centrations, absorption and distribution, but more clinical studies are needed to be performed 
to confirm the information [48] (Figure 5).
Figure 4. Structure of: (A) alpha lipoic acid structure and (B) dihydrolipoic acid.
Figure 5. Curcumin structure.
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4.12.2.1. Antioxidant mechanism of ALA and curcumin
The alpha lipoic acid and curcumin substances are OS scavengers through four mecha-
nisms: (1) radical adduct formation (RAF), (2) hydrogen transfer (HT), (3) single electron 
transfer (SET) and (4) environments of different polarity. All these activities contribute to 
an exogenous reduction of ROS and RNS, modulating redox signaling, decreasing inflam-
mation and mitochondrial lesion and modulating epithelial mesenchymal transition, 
which play a key role in the instauration of permanent lesion and progressive pain in the 
patient [49].
4.12.2.2. Clinical studies using antioxidants in CTS
Several investigators have reported favorable results with ALA as monotherapy or in com-
bination with other antioxidants in CTS; the clinical trial conducted by Pajardi et al. [50] 
reported satisfactory clinical recovery from CTS with a combination of ALA, curcumin and 
vitamin B complex. Di Geronimo et al. [51] showed that clinical symptoms and neurophysi-
ological outcomes were superior in a group that took a combination of ALA and gamma-
linoleic acid compared with the group that took vitamin B complex. Notarnicola et al. [52] 
verified the efficiency of shock wave therapy versus nutraceutical therapy composed of ALA, 
linoleic acid, quercetin and Echinacea in CTS. Both groups showed clinical and electrodiag-
nostic improvement. Boriani et al. [53] recently published the effect of ALA in carpal tunnel 
syndrome, they used ALA as a monotherapy after surgery for 40 days, they showed good 
electrophysiological and clinical response; however, treatments with a longer period of time 
are necessary to observe the recovery of the nerve because during the first 30 days after sur-
gery, the healing progress induces an immature and intense fibrosis; however, the recovery 
of the nerve does not occur.
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